Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan

被引：1

作者：

Nakane, Keita ^{[1
]}

Taniguchi, Kazuki ^{[2
]}

Nezasa, Minori ^{[3
]}

Enomoto, Torai ^{[1
,3
]}

Yamada, Toyohiro ^{[4
]}

Tomioka-Inagawa, Risa ^{[5
]}

Niwa, Kojiro ^{[6
]}

Tomioka, Masayuki ^{[1
,7
]}

Ishida, Takashi ^{[8
]}

Nagai, Shingo ^{[9
]}

Yokoi, Shigeaki ^{[10
]}

Taniguchi, Tomoki ^{[1
]}

Kawase, Makoto ^{[1
]}

Kawase, Kota ^{[1
]}

Iinuma, Koji ^{[1
]}

Tobisawa, Yuki ^{[1
]}

Koie, Takuya ^{[1
]}

机构：

[1] Gifu Univ, Dept Urol, Grad Sch Med, Gifu 5011194, Japan

[2] Gifu Prefectural Gen Med Ctr, Dept Urol, Gifu 5008717, Japan

[3] Matsunami Gen Hosp, Dept Urol, Gifu 5016062, Japan

[4] Ogaki Municipal Hosp, Dept Urol, Ogaki 5038502, Japan

[5] Japanese Red Cross Takayama Hosp, Dept Urol, Takayama 5068550, Japan

[6] Daiyukai Daiichi Hosp, Dept Urol, Ichinomiya 4918551, Japan

[7] Chuno Kosei Hosp, Dept Urol, Seki 5013802, Japan

[8] Gifu Municipal Hosp, Dept Urol, Gifu 5008513, Japan

[9] Toyota Mem Hosp, Dept Urol, Toyota 4718513, Japan

[10] Cent Japan Int Med Ctr, Dept Urol, Minokamo 5058510, Japan

来源：

CANCERS | 2024年 / 16卷 / 15期

关键词：

retrospective multicenter cohort study; advanced urothelial carcinoma; enfortumab vedotin; overall survival; prognostic factor; neutrophil-to-lymphocyte ratio; dysgeusia; CHEMOTHERAPY; CRITERIA; CANCER; PEMBROLIZUMAB; METHOTREXATE; VINBLASTINE; DOXORUBICIN; CISPLATIN; NIVOLUMAB; NECTIN-4;

D O I：

10.3390/cancers16152648

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Randomized phase III trial results have demonstrated enfortumab vedotin (EV), an antibody-drug conjugate (ADC) consisting of an anti-Nectin-4 human IgG1 monoclonal antibody and monomethyl auristatin E, is a useful treatment for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) that progressed after immune checkpoint inhibitor (ICI) therapies. This multicenter retrospective cohort study aimed to identify predictive factors for the efficacy of EV therapy and prolonged overall survival (OS) of patients in clinical practice. This study included patients with la/mUC who received ICI treatment. Patients who subsequently received EV treatment, those who received non-EV chemotherapy, and those who received no treatment were defined as EV, non-EV, and best supportive care (BSC) groups, respectively. The median OS was 20, 15, and 7 months in the EV, non-EV, and BSC groups, respectively (p < 0.001). Patients with la/mUC who had a complete or partial response after EV treatment had a significantly prolonged OS compared with those with stable or progressive disease. Univariate analysis showed age, neutrophil-to-lymphocyte ratio (NLR), dysgeusia, and rash as independent predictors of OS improvement. NLR and dysgeusia were independent predictors of OS after EV in multivariate analysis. Patients without these factors had a significantly prolonged OS compared to those with both factors. In real-world practice, EV therapy is an effective treatment for patients with la/mUC after ICI treatment.

引用

页数：13

共 33 条

[1] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[2] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[3]

Bladder Cancer, 2024, NCCN Guidelines

[4]

Cancer Institute N, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

[5]

Cancer Stat Facts: Bladder Cancer, 2023, NIH NCI: Surveillance, Epidemiology, and End Results Program

[6] The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma [J].

Cathomas, Richard ;

Lorch, Anja ;

Bruins, Harman M. ;

Comperat, Eva M. ;

Cowan, Nigel C. ;

Efstathiou, Jason A. ;

Fietkau, Rainer ;

Gakis, Georgios ;

Hernandez, Virginia ;

Espinos, Estefania Linares ;

Neuzillet, Yann ;

Ribal, Maria J. ;

Rouanne, Matthieu ;

Thalmann, George N. ;

van der Heijden, Antoine G. ;

Veskimae, Erik ;

Witjes, J. Alfred ;

Milowsky, Matthew I. .

EUROPEAN UROLOGY, 2022, 81 (01) :95-103

[7] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models [J].

Challita-Eid, Pia M. ;

Satpayev, Daulet ;

Yang, Peng ;

An, Zili ;

Morrison, Karen ;

Shostak, Yuriy ;

Raitano, Arthur ;

Nadell, Rossana ;

Liu, Wendy ;

Lortie, Dawn Ratay ;

Capo, Linnette ;

Verlinsky, Alla ;

Leavitt, Monica ;

Malik, Faisal ;

Avina, Hector ;

Guevara, Claudia I. ;

Dinh, Nick ;

Karki, Sher ;

Anand, Banmeet S. ;

Pereira, Daniel S. ;

Joseph, Ingrid B. J. ;

Donate, Fernando ;

Morrison, Kendall ;

Stover, David R. .

CANCER RESEARCH, 2016, 76 (10) :3003-3013

[8] Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy [J].

Chatterjee, Subhajit ;

Sinha, Saptarshi ;

Kundu, Chanakya Nath .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 911

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan [J].

Hirasawa, Yosuke ;

Adachi, Takahiro ;

Hashimoto, Takeshi ;

Fukuokaya, Wataru ;

Koike, Yuhei ;

Yata, Yuji ;

Komura, Kazumasa ;

Uchimoto, Taizo ;

Tsujino, Takuya ;

Nishimura, Kazuki ;

Takahara, Kiyoshi ;

Saruta, Masanobu ;

Fujita, Kazutoshi ;

Hashimoto, Mamoru ;

Uemura, Hirotsugu ;

Shiroki, Ryoichi ;

Azuma, Takashi ;

Kimura, Takahiro ;

Ohno, Yoshio .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (04)

← 1 2 3 4 →